Cbdmd, Inc. (YCBD) — SEC Filings
Cbdmd, Inc. (YCBD) — 40 SEC filings. Latest: S-1/A (Dec 22, 2025). Includes 21 8-K, 6 10-Q, 2 S-1/A.
Overview
Cbdmd, Inc. (YCBD) is a publicly traded company tracked on ReadTheFiling. The most recent enriched filing is a S-1/A filed on Dec 22, 2025: cbdMD, Inc. (YCBD) filed an S-1/A on December 22, 2025, for the potential resale of up to 1,700,000 shares of common stock by selling shareholders. These shares are issuable upon conversion of Series B Convertible Preferred Stock, which was sold on September 29, 2025, for aggregate gross proceeds of
Sentiment Summary
Across 40 filings, the sentiment breakdown is: 7 bearish, 30 neutral, 3 mixed. The dominant filing sentiment for Cbdmd, Inc. is neutral.
Filing Type Overview
Cbdmd, Inc. (YCBD) has filed 2 S-1/A, 2 10-K, 21 8-K, 2 S-1, 6 10-Q, 2 DEF 14A, 2 10-K/A, 2 8-K/A, 1 DEFA14A with the SEC between Jan 2024 to Dec 2025.
Filings by Year
Recent SEC Filings (40)
Risk Profile
Risk Assessment: Of YCBD's 38 recent filings, 7 were flagged as high-risk, 17 as medium-risk, and 14 as low-risk. The overall risk profile suggests moderate risk with a balanced mix of positive and cautionary disclosures.
Key Executives
- T. Ronan Kennedy
- Brian A. Pearlman, Esq.
- Brian S. Bernstein, Esq.
- Brian Pearlman
- Brian S. Bernstein
Industry Context
The hemp-derived cannabinoid industry faces significant regulatory uncertainty, as highlighted by recent federal actions. Companies are navigating evolving state-level regulations for products like THC beverages, with brands like cbdMD's Oasis expanding into new markets. Competition exists across various product categories, from CBD to THC beverages, with varying degrees of profitability and market acceptance.
Top Tags
CBD (6) · financials (6) · corporate-governance (5) · 10-Q (4) · 8-K (4) · Hemp (3) · Cannabinoids (3) · Regulatory Risk (3) · equity-sale (3) · filing (3)
Key Numbers
| Metric | Value | Context |
|---|---|---|
| Shares of common stock for resale | 1,700,000 | Issuable upon conversion of Series B Preferred Stock by Selling Shareholders |
| Proceeds from Series B Preferred Stock | $1.7M | Used for working capital and general corporate purposes |
| GAAP operating loss in fiscal 2025 | $2.1M | Reduced from $3.3 million in fiscal 2024 |
| Percentage of common stock from Series A conversion | 91% | Secured sufficient votes to convert Series A Convertible Preferred and accrued dividends |
| Common stock price | $1.93 | Last reported sales price on NYSE American on December 18, 2025 |
| Common stock outstanding | 8,959,410 | Immediately prior to this offering as of December 19, 2025 |
| Proceeds from Series C Preferred Stock | $2.25M | Issued to two institutional investors on December 18, 2025 |
| Identified corporate overhead savings | $200,000 | To be implemented in early fiscal 2026 |
| GAAP operating loss for fiscal 2025 | $2.1 million | reduced from $3.3 million in fiscal 2024 |
| GAAP operating loss for fiscal 2024 | $3.3 million | reduced to $2.1 million in fiscal 2025 |
| percentage of common stock | 91% | converted from Series A Convertible Preferred and accrued dividends in April 2025 |
| corporate overhead savings | $200,000 | identified for implementation in early 2026 |
| percentage of company's revenue | 40-45% | derived from full-spectrum SKUs, potentially impacted by federal action in November 2025 |
| brand development, sponsorships and marketing spend | $4.4 million | in fiscal year 2025 |
| percentage of sales from e-commerce | 77% | in fiscal 2025, down from 80% in fiscal 2024 |
Related Companies
Frequently Asked Questions
What are the latest SEC filings for Cbdmd, Inc. (YCBD)?
Cbdmd, Inc. has 40 recent SEC filings from Jan 2024 to Dec 2025, including 21 8-K, 6 10-Q, 2 S-1/A. Each filing includes an AI-generated plain-English summary.
What is the overall sentiment of YCBD filings?
Across 40 filings, the sentiment breakdown is: 7 bearish, 30 neutral, 3 mixed. The dominant sentiment is neutral.
Where can I find Cbdmd, Inc. SEC filings explained simply?
ReadTheFiling provides AI-powered plain-English summaries of all Cbdmd, Inc. (YCBD) SEC filings, including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, and insider trades.
What are the key financial highlights for Cbdmd, Inc.?
Key financial highlights from Cbdmd, Inc.'s most recent 10-K include metrics such as revenue, net income, EPS, and debt ratios. Visit the filing detail page for the full breakdown.
What is the investment thesis for YCBD?
The investment thesis for YCBD includes bull, base, and bear case scenarios derived from AI analysis of recent SEC filings.
Who are the key executives at Cbdmd, Inc.?
Key executives identified across Cbdmd, Inc.'s filings include T. Ronan Kennedy, Brian A. Pearlman, Esq., Brian S. Bernstein, Esq., Brian Pearlman, Brian S. Bernstein.
What are the main risk factors for Cbdmd, Inc. stock?
Of YCBD's 38 assessed filings, 7 were flagged high-risk, 17 medium-risk, and 14 low-risk.
What are recent predictions and forward guidance from Cbdmd, Inc.?
Forward guidance and predictions for Cbdmd, Inc. are extracted from SEC filings as they are enriched.